A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521752-26-00

Enrollment

Registered

2026-03-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complement-Mediated Kidney Disease

Brief summary

Incidence and severity of TEAEs

Detailed description

1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time

Interventions

DRUGADX-038

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence and severity of TEAEs	—

Secondary

Measure	Time frame
1. Change from baseline in UPCR as measured by 24-hour urine over time, 2. Change from baseline in UPCR as measured by spot urine over time	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 3, 2026